AR031437A1 - Metodo de obtencion de agregados antigenicos y su uso en formulaciones - Google Patents
Metodo de obtencion de agregados antigenicos y su uso en formulacionesInfo
- Publication number
- AR031437A1 AR031437A1 ARP010105554A ARP010105554A AR031437A1 AR 031437 A1 AR031437 A1 AR 031437A1 AR P010105554 A ARP010105554 A AR P010105554A AR P010105554 A ARP010105554 A AR P010105554A AR 031437 A1 AR031437 A1 AR 031437A1
- Authority
- AR
- Argentina
- Prior art keywords
- structures
- resulting
- obtaining
- formulations
- aggregation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se relaciona con el método para la obtencion de estructuras antigénicas de naturaleza agregada, capaces de potenciar la respuesta inmune a antígenos agregados administrados por vía sistémica y/o mucosal, generando potentes respuestas inmunes así como estructuras químicas resultantes de la aplicacion de este método, formulaciones obtenidas a partir de dichas estructuras y uso de las mismas. El método describe la obtencion de nuevas estructuras antigénicas agregadas a partir del uso de agentes o compuestos agregantes, delipidantes u oxidantes que permiten la liberacion de lípidos de la partícula y la agregacion de las mismas de forma heterogénea, seleccionándose posteriormente agregados de partículas de tallas entre 30 y 500 nm mediante un proceso de exclusion molecular. También se puede provocar el estado de agregacion en el interior de la levadura variando las condiciones de incubacion. Las estructuras resultantes pueden utilizarse convenientemente adyuvadas o en una formulacion donde pueden introducirse varios antígenos, encontrándose un efecto sinérgico entre estos componentes con respecto a la inmunogenicidad de la respuesta obtenida. Además la preparacion puede contener, estabilizadores y preservantes. Las estructuras antigénicas resultantes son aplicables en la industria farmacéutica como formulaciones vacunales preventivas o terapéuticas tanto para uso humano como veterinario y como parte de sistemas de diagnostico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20000279A CU23002A1 (es) | 2000-12-01 | 2000-12-01 | Método de obtención de agregados antigénicos y su uso en formulaciones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031437A1 true AR031437A1 (es) | 2003-09-24 |
Family
ID=5459569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105554A AR031437A1 (es) | 2000-12-01 | 2001-11-29 | Metodo de obtencion de agregados antigenicos y su uso en formulaciones |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040202676A1 (es) |
| EP (1) | EP1346727B1 (es) |
| JP (1) | JP4974441B2 (es) |
| KR (1) | KR100873675B1 (es) |
| CN (1) | CN1253206C (es) |
| AR (1) | AR031437A1 (es) |
| AT (1) | ATE465752T1 (es) |
| AU (2) | AU2002221518B2 (es) |
| BR (1) | BRPI0115859B8 (es) |
| CA (1) | CA2429543C (es) |
| CU (1) | CU23002A1 (es) |
| DE (1) | DE60141978D1 (es) |
| ES (1) | ES2342150T3 (es) |
| PT (1) | PT1346727E (es) |
| RU (1) | RU2266754C2 (es) |
| WO (1) | WO2002043756A2 (es) |
| ZA (1) | ZA200303948B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23405A1 (es) * | 2003-10-20 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas para uso terapéutico |
| EP1652914A1 (en) * | 2004-10-27 | 2006-05-03 | Berna Biotech AG | Virosome particles comprising antigens from influenza virus and Hepatitis B virus |
| US9603921B2 (en) | 2004-10-27 | 2017-03-28 | Janssen Vaccines Ag | Virosome particles comprising antigens from influenza virus and hepatitis b virus |
| ES2401706T3 (es) * | 2005-07-27 | 2013-04-23 | Eli Lilly And Company | Un método de tratar células cancerosas para crear una célula cancerosa modificada que provoca una respuesta inmunogénica |
| CU23740A1 (es) * | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
| AR107262A1 (es) | 2016-01-27 | 2018-04-11 | Lilly Co Eli | Inactivación de patógenos por delipidación |
| CU24454B1 (es) | 2016-03-31 | 2019-11-04 | Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma | Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8421282D0 (en) * | 1984-08-22 | 1984-09-26 | Connaught Lab | Multispecific antigenic proteins |
| EP0231039B1 (en) | 1986-01-14 | 1992-01-08 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Process for preparing immunological complexes and pharmaceutical composition containing these complexes |
| US5728804A (en) * | 1995-06-02 | 1998-03-17 | Research Corporation Technologies, Inc. | Use of cyclodextrins for protein renaturation |
| JP2004500868A (ja) * | 2000-06-22 | 2004-01-15 | セルテック ファーマスーティカルズ リミテッド | Ｂ型肝炎コア抗原の修飾 |
| US8092734B2 (en) * | 2004-05-13 | 2012-01-10 | Aptina Imaging Corporation | Covers for microelectronic imagers and methods for wafer-level packaging of microelectronics imagers |
-
2000
- 2000-12-01 CU CU20000279A patent/CU23002A1/es unknown
-
2001
- 2001-11-29 JP JP2002545726A patent/JP4974441B2/ja not_active Expired - Lifetime
- 2001-11-29 DE DE60141978T patent/DE60141978D1/de not_active Expired - Lifetime
- 2001-11-29 BR BR0115859-7 patent/BRPI0115859B8/pt not_active IP Right Cessation
- 2001-11-29 EP EP01998363A patent/EP1346727B1/en not_active Expired - Lifetime
- 2001-11-29 CN CNB018198236A patent/CN1253206C/zh not_active Expired - Lifetime
- 2001-11-29 RU RU2003119455/13A patent/RU2266754C2/ru active
- 2001-11-29 US US10/433,492 patent/US20040202676A1/en not_active Abandoned
- 2001-11-29 KR KR1020037007094A patent/KR100873675B1/ko not_active Expired - Lifetime
- 2001-11-29 AT AT01998363T patent/ATE465752T1/de active
- 2001-11-29 AU AU2002221518A patent/AU2002221518B2/en not_active Ceased
- 2001-11-29 CA CA2429543A patent/CA2429543C/en not_active Expired - Fee Related
- 2001-11-29 AR ARP010105554A patent/AR031437A1/es not_active Application Discontinuation
- 2001-11-29 PT PT01998363T patent/PT1346727E/pt unknown
- 2001-11-29 AU AU2151802A patent/AU2151802A/xx active Pending
- 2001-11-29 WO PCT/CU2001/000009 patent/WO2002043756A2/es not_active Ceased
- 2001-11-29 ES ES01998363T patent/ES2342150T3/es not_active Expired - Lifetime
-
2003
- 2003-05-21 ZA ZA200303948A patent/ZA200303948B/en unknown
-
2007
- 2007-10-10 US US11/870,088 patent/US20090104223A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2429543A1 (en) | 2003-05-20 |
| ATE465752T1 (de) | 2010-05-15 |
| AU2151802A (en) | 2002-06-11 |
| DE60141978D1 (de) | 2010-06-10 |
| US20090104223A1 (en) | 2009-04-23 |
| BRPI0115859B1 (pt) | 2020-10-13 |
| EP1346727A2 (en) | 2003-09-24 |
| CN1477972A (zh) | 2004-02-25 |
| WO2002043756A2 (es) | 2002-06-06 |
| ZA200303948B (en) | 2004-03-30 |
| WO2002043756A3 (es) | 2003-01-09 |
| CA2429543C (en) | 2012-07-10 |
| EP1346727B1 (en) | 2010-04-28 |
| KR20030068161A (ko) | 2003-08-19 |
| RU2266754C2 (ru) | 2005-12-27 |
| CN1253206C (zh) | 2006-04-26 |
| AU2002221518B2 (en) | 2006-06-01 |
| KR100873675B1 (ko) | 2008-12-11 |
| US20040202676A1 (en) | 2004-10-14 |
| BR0115859A (pt) | 2003-12-30 |
| JP2004529861A (ja) | 2004-09-30 |
| CU23002A1 (es) | 2004-11-18 |
| JP4974441B2 (ja) | 2012-07-11 |
| ES2342150T3 (es) | 2010-07-02 |
| BRPI0115859B8 (pt) | 2021-05-25 |
| PT1346727E (pt) | 2010-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2349342C2 (ru) | Менингококковые вакцины для введения через слизистую оболочку | |
| Goel et al. | Cell mediated immune response after challenge in Omp25 liposome immunized mice contributes to protection against virulent Brucella abortus 544 | |
| AR032597A1 (es) | Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli | |
| ES2180703T5 (es) | Composiciones de vacunas para mamiferos que comprenden escualeno o escualano, un fosfolipido y un tensioactivo como adyuvante. | |
| BR112014007927B1 (pt) | Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições | |
| ES2233955T3 (es) | Adyuvantes para vacunas viricas. | |
| HU202119B (en) | Adjuvant mixture and process for producing vaccine comprising same | |
| UY39192A (es) | Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende | |
| Azuar et al. | Cholic acid-based delivery system for vaccine candidates against group A streptococcus | |
| JP7158853B2 (ja) | 対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物 | |
| Ochoa et al. | Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice | |
| AR031437A1 (es) | Metodo de obtencion de agregados antigenicos y su uso en formulaciones | |
| WO2003051394A3 (en) | Calcium phosphate particles as mucosal adjuvants | |
| Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
| ES2566646T3 (es) | Vacunas en nanoemulsión | |
| US3594471A (en) | Novel adjuvant vaccine and method of producing the same | |
| CN104427998B (zh) | 佐剂 | |
| JP7016317B2 (ja) | アジュバント組成物 | |
| CA2931139A1 (en) | Swine vaccine against prrs and lawsonia intracellularis | |
| WO2023126026A3 (zh) | Epa-ee纳米脂质组合物、及其制剂、制备方法和应用 | |
| CN113679831B (zh) | 一种注射用水包油型乳剂黏膜疫苗及其制备方法和应用 | |
| AR031182A1 (es) | Metodo de obtencion de estructuras antigenicas que potencian la reactividad cruzada especifica y su uso en formulaciones | |
| JP2016222704A (ja) | 改善されたワクチン組成物 | |
| EP1843787B1 (en) | Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines | |
| Mavandadnejad et al. | Biosynthesis of SeNPs by Mycobacterium bovis and their enhancing effect on the immune response against HBs antigens: an in vivo study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |